BiomX (NYSEMKT:PHGE) Trading Up 4.6% – Still a Buy?

BiomX Inc. (NYSEMKT:PHGE) shares shot up 4.6% during mid-day trading on Tuesday . The company traded as high as $0.77 and last traded at $0.77. 62,143 shares changed hands during trading, a decline of 9% from the average session volume of 68,601 shares. The stock had previously closed at $0.74.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of BiomX in a research report on Friday, August 16th.

BiomX Price Performance

The company has a 50-day moving average of $0.94 and a 200-day moving average of $2.21. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The stock has a market cap of $13.42 million, a price-to-earnings ratio of -0.17 and a beta of 1.31.

Institutional Investors Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Ikarian Capital LLC purchased a new stake in BiomX Inc. (NYSEMKT:PHGE) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned 19.59% of BiomX at the end of the most recent reporting period. Institutional investors and hedge funds own 40.57% of the company’s stock.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.